Nan Li
992 posts
Today, we announce Tamarind Bio’s $13.6M Series A, led by @_DimensionCap, with participation from @ycombinator. Tamarind has now become the trusted platform for molecular AI inference, serving tens of thousands of scientists, including 8 of the top 20 pharma, dozens of biotechs and research organizations. Since last year, we’ve grown revenue 7x and are grateful to work with world-class biopharma R&D organizations like @Bayer, @Boehringer, and Adimab. — When we started two years ago, a few brave biotechs took a chance with us. Hoping this new company, providing easy access to computational drug discovery tools, would enable their scientists to apply foundation models to real therapeutic applications. Since then, our library of AI models has grown to hundreds, not just open-source tools, but also our users’ internal protocols, proprietary models trained on users’ own data, pipelines of multiple models together and more! Now, we are doubling down on our commitment to building the core AI and data infrastructure to power the next generation of medicines. We will continue to support open models, strengthening them with proprietary data, and prioritize access to all scientists. Join us as we build the infrastructure for all AI-powered drug discovery.
Today, we announce Tamarind Bio’s $13.6M Series A, led by @_DimensionCap, with participation from @ycombinator. Tamarind has now become the trusted platform for molecular AI inference, serving tens of thousands of scientists, including 8 of the top 20 pharma, dozens of biotechs and research organizations. Since last year, we’ve grown revenue 7x and are grateful to work with world-class biopharma R&D organizations like @Bayer, @Boehringer, and Adimab. — When we started two years ago, a few brave biotechs took a chance with us. Hoping this new company, providing easy access to computational drug discovery tools, would enable their scientists to apply foundation models to real therapeutic applications. Since then, our library of AI models has grown to hundreds, not just open-source tools, but also our users’ internal protocols, proprietary models trained on users’ own data, pipelines of multiple models together and more! Now, we are doubling down on our commitment to building the core AI and data infrastructure to power the next generation of medicines. We will continue to support open models, strengthening them with proprietary data, and prioritize access to all scientists. Join us as we build the infrastructure for all AI-powered drug discovery.
We raised $130M in Series B funding at a $1.3B valuation to build the computer aided design suite for molecules. The round was led by @GeneralCatalyst & @OakHCFT along with existing investors @ThriveCapital, @OpenAI, @_DimensionCap, @Neo, @lachygroom, @MenloVentures, @svangel, and Yosemite. We're also joined by new investors including @EmCollective and Glade Brook.
Today we’re launching @chaidiscovery, led by @joshim5 & his polymathic world class cofounders. We’re also open sourcing Chai-1: a state of the art frontier model for biomolecular interactions. @_DimensionCap has co-led the founding round alongside Thrive & OpenAI
Today, we’re releasing new data showing that Chai-2 can design antibodies against challenging targets with atomic precision. >86% of our designs possess industry-standard drug-quality properties without any optimization. Thread👇
Today, we announce the closing of a $213M Series D financing round. Thank you to our investors for supporting the advancement of our portfolio of clinical and preclinical medicines designed to precisely treat the drivers of complex autoimmune diseases. odysseytx.com/odyssey-therap…
